Research library / Rapamycin

CC Small or few human trials. Promising, not proven. How we grade →Animal study · Mice treated for 3 months from 20 months of age

Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice

A Bitto, T Ito, V Pineda, N LeTexier, H Huang, E Sutlief et al. eLife. 2016.

Published Sources checked 1 sourceEverstack research teamHow we work

In plain language
Three months of rapamycin in middle-aged male mice raised median remaining life by 60% from the end of treatment (16% from birth); at one dose, females did not live longer and had more aggressive blood cancers.
Limits
Mouse data, single lab, injected drug.
Which of our grades it feeds
Source
doi.org/10.7554/eLife.16351 · PubMed 27549339 · Free full text

Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack. We sell some of what we grade.